Copyright
©The Author(s) 2018.
World J Hepatol. Nov 27, 2018; 10(11): 856-866
Published online Nov 27, 2018. doi: 10.4254/wjh.v10.i11.856
Published online Nov 27, 2018. doi: 10.4254/wjh.v10.i11.856
Table 2 Adjusted logistic regression for factors associated with virological treatment failure
Covariables | Model 1 | Model 2 | Model 3 | Model 4 | ||||
OR (95%CI) | P value | OR (95% CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | |
n = 538 | n = 538 | n = 526 | n = 395 | |||||
Age at treatment initiation (per 10 yr) | 1.2 (0.6-2.4) | 0.58 | 1.3 (0.7-2.5) | 0.48 | 1.2 (0.6-2.4) | 0.53 | 1.6 (0.7-4.0) | 0.29 |
Ribavirin vs no ribavirin | 1.0 (0.3-3.0) | 0.97 | 1.1 (0.3-3.2) | 0.93 | 1.0 (0.3-3.0) | 0.97 | 1.4 (0.4-5.5) | 0.61 |
Male sex vs female | 1.0 (0.4-2.8) | 0.98 | 0.9 (0.3-2.7) | 0.92 | 1.0 (0.3-2.8) | 0.97 | 0.8 (0.2-2.7) | 0.69 |
Treatment duration 24 wk vs 12 wk | 0.4 (0.1-1.4) | 0.15 | 0.5 (0.2-1.5) | 0.21 | 0.4 (0.1-1.4) | 0.16 | 0.2 (0.0-1.0) | 0.05 |
Platelet count < 100 Giga/L vs ≥ 100 | 6.5 (1.8-22.6) | 0.004 | ||||||
Cirrhosis vs no cirrhosis | 1.4 (0.5-3.9) | 0.51 | ||||||
HIV-RNA detectable vs undetectable | 2.1 (0.7-5.9) | 0.17 | ||||||
Severe cirrhosis vs no severe cirrhosis | 2.1 (0.4-10.3) | 0.35 | ||||||
HCV genotype 3 vs others | 0.9 (0.1-7.5) | 0.91 |
- Citation: Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L, ANRS CO13 Hepavih study Group. Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World J Hepatol 2018; 10(11): 856-866
- URL: https://www.wjgnet.com/1948-5182/full/v10/i11/856.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i11.856